Protection from shots like the flu vaccine typically takes a couple of weeks to kick in, so getting one now may offer ...

Phase 2a study to evaluate safety and immunogenicity of a booster dose of influenza vaccine candidate OVX836, three to five years after initial administration Enrollment of over 150 participants ...

Vaxart ( (VXRT) ) has released its Q3 earnings. Here is a breakdown of the information Vaxart presented to its investors. Vaxart, Inc. is a ...

Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has announced that ...

The non-qualified stock option is an option to purchase 64,150 shares of Novavax's common stock with a per share exercise price of $9.01, the closing price of Novavax's common stock on the Nasdaq ...

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: VXRT) today announced it will provide a business update and report financial results ...

On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for ...

In addition, our standalone influenza vaccine program is based on a platform that has demonstrated enhanced immunogenicity in ...